Literature DB >> 3498741

Inhibition of the activation of Hageman factor (factor XII) by peripheral blood cells.

O D Ratnoff1, M M Emanuelson, N P Ziats.   

Abstract

Suspensions of peripheral blood mononuclear cells (PBMC), monocytes, T or B lymphocytes, platelets or granulocytes, and cell-depleted supernatant fluids of these suspensions inhibited activation of Hageman factor (HF, Factor XII) by ellagic acid, a property not shared by erythrocytes. PBMC also inhibited HF activation by glass or sulfatides. Contaminating platelets may have contributed to inhibition by PBMC. Elaboration of agents inhibiting HF activation required metabolically active cells. The inhibitor(s) in PBMC supernates were not identified with known agents, but had properties of a nonenzymatic protein. PBMC supernates did not contain fibrinogen, nor alter the thrombin, prothrombin, or partial thromboplastin times of normal plasma, amidolysis by activated plasma thromboplastin antecedent (Factor XIa) or activated Stuart factor (Factor Xa) or esterolysis by C1 (C1 esterase); they inhibited plasmin minimally. These experiments suggest that peripheral blood cells may impede intravascular coagulation. Whether this property helps maintain the fluidity of blood is unclear.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3498741      PMCID: PMC442363          DOI: 10.1172/JCI113177

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  Activation of human factor X (Stuart factor) by a protease from Russell's viper venom.

Authors:  R G Di Scipio; M A Hermodson; E W Davie
Journal:  Biochemistry       Date:  1977-11-29       Impact factor: 3.162

2.  Generation of kinin-like agents by chondroitin sulfate, heparin, chitin sulfate, and human articular cartilage: possible pathophysiologic implications.

Authors:  R W Moskowitz; H J Schwartz; B Michel; O D Ratnoff; T Astrup
Journal:  J Lab Clin Med       Date:  1970-11

3.  Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator.

Authors:  C D Forbes; J Pensky; O D Ratnoff
Journal:  J Lab Clin Med       Date:  1970-11

4.  The isolation of IgG from mammalian sera with the aid of caprylic acid.

Authors:  M Steinbuch; R Audran
Journal:  Arch Biochem Biophys       Date:  1969-11       Impact factor: 4.013

5.  Establishment and characterization of a human histiocytic lymphoma cell line (U-937).

Authors:  C Sundström; K Nilsson
Journal:  Int J Cancer       Date:  1976-05-15       Impact factor: 7.396

6.  Antifactor Xa activity measured with amidolytic methods.

Authors:  O R Odegård; M Lie; U Abildgaard
Journal:  Haemostasis       Date:  1976

7.  Serum inhibitor of C'1-esterase in health and disease.

Authors:  V H Donaldson
Journal:  J Lab Clin Med       Date:  1966-09

8.  Properties of washed human platelets.

Authors:  R L Kinlough-Rathbone; J F Mustard; M A Packham; D W Perry; H J Reimers; J P Cazenave
Journal:  Thromb Haemost       Date:  1977-04-30       Impact factor: 5.249

9.  Activation of Hageman factor (factor XII) by sulfatides and other agents in the absence of plasma proteases.

Authors:  F España; O D Ratnoff
Journal:  J Lab Clin Med       Date:  1983-07

10.  In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E.

Authors:  Y Hojima; C G Cochrane; R C Wiggins; K F Austen; R L Stevens
Journal:  Blood       Date:  1984-06       Impact factor: 22.113

View more
  3 in total

1.  Inhibition of the activation of Hageman factor (factor XII) by human vascular endothelial cell culture supernates.

Authors:  O D Ratnoff; B Everson; P Embury; N P Ziats; J M Anderson; M M Emanuelson; C J Malemud
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

2.  Why does the blood not coagulate?

Authors:  O D Ratnoff
Journal:  West J Med       Date:  1993-02

3.  Endothelial cells produce a substance that inhibits contact activation of coagulation by blocking the activation of Hageman factor.

Authors:  J Kleniewski; V H Donaldson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.